CHICAGO — A Fas inhibitor showed strong efficacy signals and demonstrated neuroprotection in patients with more than 8 days of macula-off rhegmatogenous retinal detachment, according to a study ...

“Based on these results, interventions that shorten the duration of the macula-off [retinal detachment], including those occurring within the first 3 days, may result in improved long-term ...

The company’s later-stage clinical development program for ONL1204 currently includes a Phase 2 study in the U.S. for the treatment of macula-off retinal detachment (NCT05730218), a condition ...

Recently, second-generation anti-VEGF agents, including brolucizumab, faricimab, and 8 mg aflibercept, have become available ...

Medically reviewed by Christine L. Larsen, MD Posterior vitreous detachment (PVD) occurs when the vitreous—a gel-like fluid in the eye—detaches from the retina. This results in eye floaters ...

The company’s later-stage clinical development program for ONL1204 currently includes a Phase 2 study in the U.S. for the treatment of macula-off retinal detachment (NCT05730218), a condition ...

The company’s later-stage clinical development program for ONL1204 currently includes a Phase 2 study in the U.S. for the treatment of macula-off retinal detachment (NCT05730218), a condition ...

The company’s later-stage clinical development program for ONL1204 currently includes a Phase 2 study in the U.S. for the treatment of macula-off retinal detachment (NCT05730218), a condition ...